This document summarizes a literature review of a study on the use of chloroquine (CQ) and hydroxychloroquine (HCQ) in pregnant and breastfeeding patients. The study was conducted by researchers from reputable medical universities, funded by the US National Institute of Health, and published in The Lancet Infectious Diseases journal. It was a randomized controlled clinical trial involving 1209 women. The study aimed to understand the impact of antimalarial drugs on pregnant women and newborns. The researchers concluded that CQ and HCQ were generally safe for pregnant and breastfeeding patients based on the results and statistical analysis, while also acknowledging limitations to the study.
This document summarizes a literature review of a study on the use of chloroquine (CQ) and hydroxychloroquine (HCQ) in pregnant and breastfeeding patients. The study was conducted by researchers from reputable medical universities, funded by the US National Institute of Health, and published in The Lancet Infectious Diseases journal. It was a randomized controlled clinical trial involving 1209 women. The study aimed to understand the impact of antimalarial drugs on pregnant women and newborns. The researchers concluded that CQ and HCQ were generally safe for pregnant and breastfeeding patients based on the results and statistical analysis, while also acknowledging limitations to the study.
This document summarizes a literature review of a study on the use of chloroquine (CQ) and hydroxychloroquine (HCQ) in pregnant and breastfeeding patients. The study was conducted by researchers from reputable medical universities, funded by the US National Institute of Health, and published in The Lancet Infectious Diseases journal. It was a randomized controlled clinical trial involving 1209 women. The study aimed to understand the impact of antimalarial drugs on pregnant women and newborns. The researchers concluded that CQ and HCQ were generally safe for pregnant and breastfeeding patients based on the results and statistical analysis, while also acknowledging limitations to the study.
2. FAISAL NUR ARIB (2020404477) 3. FATIKA SURYANDARI (2020404478) 4. FAUZAH LAMH WAHIDAH (2020404479) LITERATUR TERSIER 1. IS THE JOURNAL CONSIDERED REPUTABLE? IS THE JOURNAL APPROPRIATE TO FIND AN ARTICLE RELATING TO THIS PARTICULAR SUBJECT? THE LANCET INFECTIOUS DISEASE IS APPROPRIATE TO FIND ABOUT INFECTIOUS DISEASE AND OTHER RELATED PROBLEMS. 2. DO THE RESEARCHERS APPEAR TO HAVE THE APPROPRIATE QUALIFICATIONS FOR UNDERTAKING THE STUDY? WAS THE RESEARCH PERFORMED IN AN APPROPRIATE MEDICAL FACILITY? YES, THEY ARE FORM REPUTABLE MEDICINAL UNIVERSITY. 3. WHAT WAS THE SOURCE OF FINANCIAL SUPPORT FOR THE STUDY? U.S. NATIONAL INSTITUTE OF HEALTH. 4. DO THE AUTHORS GIVE SUFFICIENT BACKGROUND INFORMATION FOR THE STUDY? DID THEY DEMONSTRATE THAT THE STUDY WAS IMPORTANT AND ETHICAL? YES, THEY WROTE IN BACKGROUND THAT MALARIA DURING PREGNANCY CAN HAVE SIGNIFICANTLY IMPACT THE HEALTH OF PREGNANT WOMEN, AND THEIR NEWBORNS. 5. Are the purpose and the objectives clearly stated and free from bias? The purpose of the study is objectives clearly state and free from bias, 6. WAS THE STUDY APPROVED BY AN INVESTIGATIONAL REVIEW BOARD? 7. DOES THE INVESTIGATOR STATE THE NULL HYPOTHESIS? IS THE ALTERNATIVE HYPOTHESIS STATED? 8. IS THE SAMPLE SIZE LARGE ENOUGH? IS THE SAMPLE REPRESENTATIVE OF THE POPULATION? YES, THE SAMPLE SIZA IS 1209 WOMEN. 10. WAS THE STUDY RANDOMIZED CORRECTLY? EVEN IF THE STUDY IS ADEQUATELY RANDOMIZED, ARE THE GROUPS (TREATMENT AND CONTROL) EQUIVALENT? YES. 11. What is the study design? Is it appropriate? Yes, it is appropriate. The study design is Randomized Controlled Clinical Trial. 12. WAS THE STUDY ADEQUATELY CONTROLLED? WERE THE CONTROLS ADEQUATE AND APPROPRIATE? 13. WAS THE STUDY ADEQUATELY BLINDED? 14. WERE APPROPRIATE DOSES AND REGIMENS USED FOR THE DISEASE STATE UNDER STUDY? YES. 18. Were appropriate statistical tests chosen to assess the data? 27. ARE ADVERSE REACTIONS REPORTED IN SUFFICIENT DETAIL? 28. ARE THE CONCLUSIONS SUPPORTED BY THE DATA? IS SOME FACTOR OTHER THAN THE STUDY TREATMENT RESPONSIBLE FOR THE OUTCOMES? YES. 29. ARE THE RESULTS BOTH STATISTICALLY AND CLINICALLY SIGNIFICANT? 30. DO THE AUTHORS DISCUSS STUDY LIMITATIONS IN THEIR CONCLUSIONS? 31. WERE APPROPRIATE REFERENCES USED? ARE REFERENCES TIMELY AND REPUTABLE? HAVE ANY OF THE STUDIES BEEN DISPROVEN OR UPDATED? DO REFERENCES CITED REPRESENT A COMPLETE BACKGROUND? YES, THE REFERENCES ARE FROM REPUTABLE JOURNAL AND AUTHORS.